Repligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million
Repligen Corporation (Nasdaq: RGEN), a leading life sciences company specializing in bioprocessing technology, has announced the acquisition of 908 Devices Inc.’s (Nasdaq: MASS) desktop portfolio, further strengthening its position in the bioprocessing industry. The acquisition includes four key desktop devices designed for process analytical technology (PAT) applications, enhancing Repligen’s ability to provide real-time monitoring and analytical solutions for its biopharmaceutical and CDMO (Contract Development and Manufacturing Organization) customers. Meanwhile, 908 Devices will continue its focus on developing and expanding its handheld device portfolio, particularly for health and safety applications.
This strategic acquisition aligns with Repligen’s ongoing commitment to integrating innovative bioprocessing solutions. The desktop devices acquired include MAVERICK and MAVEN, which are used for real-time monitoring and control of critical bioprocess parameters. Additionally, the acquisition includes REBEL, an at-line cell culture media analyzer, and ZipChip, a high-resolution sample separations device that supports characterization of product quality attributes. These tools will bolster Repligen’s differentiated PAT portfolio, enabling customers to optimize biopharmaceutical development and improve manufacturing efficiencies.
Olivier Loeillot, President and Chief Executive Officer at Repligen, expressed his enthusiasm about the acquisition, stating, “We are really excited to onboard the 908 bioprocessing team and the four differentiated upstream PAT technologies that are commercialized today. They are the perfect complement to our downstream analytics portfolio and will enable Repligen to further penetrate a broad set of modalities and offer analytics solutions across the entire bioprocess workflow. This asset acquisition is a true win-win for both organizations, and a significant step forward for Repligen as our customers increasingly embed digitization technologies in their production processes.”
Kevin J. Knopp, CEO and Co-founder of 908 Devices, also commented on the transaction, emphasizing the synergy between Repligen’s bioprocessing leadership and the acquired desktop technologies. “Repligen’s leadership in commercializing innovative solutions that advance bioprocessing is a great fit for our novel desktop devices and our bioprocessing team. I wish them continued success,” Knopp stated. “Going forward, 908 Devices will continue to advance chemical detection at the point of need with our handheld analytical devices in vital health and safety applications.”
Transaction Terms and Advisors
Under the terms of the agreement, Repligen will pay $70 million in cash for the acquisition of the desktop asset portfolio. The transaction represents a strategic investment in process analytics and reinforces Repligen’s vision of offering comprehensive solutions across the bioprocessing workflow.
Financial and legal advisors played a key role in facilitating this acquisition. Centerview Partners LLC served as the financial advisor to Repligen Corporation, while Goodwin Procter acted as its legal counsel. On the other side, Perella Weinberg Partners provided financial advisory services to 908 Devices Inc., with Paul Hastings LLP serving as its legal counsel.
Industry Impact and Strategic Implications
The integration of these advanced analytical tools into Repligen’s existing product lineup is expected to provide significant benefits to biopharmaceutical manufacturers. The acquisition highlights the growing importance of process analytical technology (PAT) in the industry, as companies seek to enhance efficiency, improve data-driven decision-making, and ensure high-quality biopharmaceutical production. The ability to perform real-time monitoring of key parameters and optimize workflows will be a major advantage for Repligen’s customers, reinforcing the company’s leadership in bioprocessing innovation.
Repligen has been actively expanding its portfolio through strategic acquisitions and organic growth, and this transaction further solidifies its position as a key player in the bioprocessing market. The integration of 908 Devices’ desktop technologies will likely accelerate advancements in digital bioprocessing, supporting automation and continuous manufacturing trends within the industry.
Webcast Information
908 Devices will discuss the divestiture of its desktop assets during its fourth-quarter 2024 financial results conference call. The call is scheduled to take place before the market opens on Tuesday, March 4, 2025, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Investors and stakeholders can access the webcast through the company’s Investor Relations website.
About Repligen Corporation
Repligen Corporation is a global leader in bioprocessing technologies, dedicated to enabling efficiencies in the development and manufacturing of biological drugs. With a strong focus on Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins, Repligen serves biopharmaceutical developers and CDMOs worldwide. Headquartered in Waltham, Massachusetts, Repligen operates multiple manufacturing facilities across the United States and key international sites in Estonia, France, Germany, Ireland, the Netherlands, and Sweden.
For more information about Repligen, visit www.repligen.com and follow the company on LinkedIn.
About 908 Devices Inc.
908 Devices Inc. specializes in purpose-built handheld and desktop devices for chemical analysis, with a strong emphasis on real-time detection applications. By focusing on portable solutions, the company supports vital health and safety applications across various industries, including forensic analysis, environmental monitoring, and military defense. As 908 Devices shifts its focus entirely to handheld solutions, it aims to continue providing cutting-edge analytical technology at the point of need.
For additional details on 908 Devices, visit www.908devices.com.
